WebJan 26, 2024 · The Journal of Clinical Oncology has published the final results of the randomized phase II trial E3311 showing that 94.9% of such patients were alive and disease-free three years later and had an … WebOct 26, 2024 · The Eastern Cooperative Oncology Group (ECOG) 3311 (NCT01898494) study was a RCT for the de-escalation of adjuvant treatment after transoral surgery (TOS) and neck dissection for HPV+ OPSCC (27 ...
Virtual Press - American Society of Clinical …
WebOct 26, 2024 · E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer … WebJul 12, 2013 · ECOG-ACRIN Cancer Research Group: ClinicalTrials.gov Identifier: NCT01898494 Other Study ID Numbers: E3311 NCI-2013-00814 ( Registry Identifier: … katanning cemetery records
E3311: No differences in survival outcomes based on ... - ecog …
WebNov 9, 2024 · The recently published ECOG 3311 trial showed that surgery can be used to safely de-escalate the adjuvant radiation dose to 50 Gy in intermediate-risk patients. In this review, we summarize and discuss the past and current clinical trials involving surgery in the treatment of HPV-positive OPSCC. Introduction WebThe diverse scientific perspectives of our world-class team inform a unique approach to generate the next generation of safe and effective therapeutics for cancer and beyond. Leadership Mani Mohindru, PhD Chief Executive Officer, Board Member Michael Lyman, PhD Sr. Vice President, Research and Development Pallavi Tawde, PhD WebSep 3, 2024 · A much larger randomized trial, ECOG-ACRIN 3311, tested a precision oncology approach to HPV-positive HNC, driven by pathologic findings at the time of surgical resection. 17 Patients with low-risk features (T1-2, N0-1, clear margins [≥ 3 mm], no extranodal excision [ENE] or perineural invasion [PNI]/lymphovascular invasion [LVI]) … lawyer office shootings